Vor Biopharma

VOR · NASDAQ

$19.03+$0.99 (+5.49%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $18.04

VOR analyst rating

BuyConsensus of 7 analysts over the last 12 months. 86% rate it a buy.

Strong buy0
Buy6
Hold1
Underperform0
Sell0

12-month price target · 9 analysts

Average $39.78 (+109.0% upside)

Low: $27.27
Now: $19.03
High: $52.50

Upgrades and downgrades

The latest rating actions, newest first

VOR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wedbush	Aug 12, 2026	Maintains	Neutral	$18.00 → $27.00	40%
HC Wainwright & Co.	May 18, 2026	Maintains	Buy	$31.00	43%
Wedbush	May 14, 2026	Maintains	Neutral	$15.00 → $18.00	40%
HC Wainwright & Co.	Apr 15, 2026	Maintains	Buy	$32.00 → $31.00	43%
Wedbush	Mar 31, 2026	Maintains	Neutral	$9.00 → $15.00	40%
Jefferies	Mar 30, 2026	Initiates	Buy	$50.00	60%
Wells Fargo	Mar 19, 2026	Initiates	Overweight	$30.00	25%
Citigroup	Jan 9, 2026	Initiates	Buy	$50.00	60%
JP Morgan	Dec 19, 2025	Maintains	Overweight	$43.00 → $40.00	48%
TD Cowen	Dec 17, 2025	Initiates	Buy	—	49%

The case for and against

Updated Oct 14, 2026

Bull case

Vor Biopharma is viewed positively because telitacicept targets a large, underpenetrated B-cell autoimmune market, with Vor estimating about 380K diagnosed US patients in gMG or Sjögren’s disease and more than 1M potential patients after indication expansion. The asset already has commercial and clinical validation in China, where it is approved in SLE in 2021, RA in 2024, and gMG in 2025, while the NEJM-published TELIGAN interim data showed a 55.0% placebo-adjusted UPCR reduction at week 39, preserved eGFR, and fewer serious adverse events. Outside China, Vor retains exclusive rights in major regions and is advancing two global Phase 3 UPSTREAM studies, with gMG topline data expected in 1H27 and Sjögren’s dosing begun in 1Q26, supporting multiple catalysts.

Bear case

Vor Biopharma is a clinical-stage company with no revenues in 1Q26 and a $5.11 per share net loss, underscoring a business model still dependent on future telitacicept success rather than current cash generation. Although it held about $491.5M in cash and short-term marketable securities at the end of 1Q26, that runway into early 2029 does not eliminate major clinical, regulatory, commercial, collaboration, dilution, and legal risks. The negative outlook reflects the possibility that telitacicept may fail to prove sufficiently efficacious or safe, may not reach sales expectations, and could face competition or manufacturing and shipment setbacks.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.